Multigene panel testing should be considered for all African-American women with triple-negative breast cancer regardless of their age or cancer history.
A new option proves effective for patients with HER2+ early breast cancer with residual disease after neoadjuvant therapy.
Join experts from Cleveland Clinic and around the world at a CME-certified official review in Hollywood, Florida.
A new imaging modality may offer a wealth of prognostic information on tumor behavior and differentiation of cancer subtypes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic oncologists conducted a new meta-analysis of breast cancer lumpectomy patients to determine the best margins to prevent additional surgery and optimize long-term survival.
Five-year follow-up data from the Prevention of Early Menopause Study shows use of goserelin, a gonadotropin hormone-releasing hor-mone agonist, along with standard chemotherapy, helps preserve fertility in women with breast cancer.
The first prospective randomized trial of scalp cooling shows that the therapy can significantly decrease chemotherapy-induced alopecia in breast cancer patients and is well tolerated.
As reported at the 2016 San Antonio Breast Cancer Symposium, results from NSABP B-42 trial contradicted previous studies and showed no benefit with letrozole use beyond five years. But investigators say longer followup is needed.
Cleveland Clinic’s Jame Abraham, MD, discusses results of the 10-year follow-up of the BCIRG-006 clinical trial, which demonstrated the significant benefit of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer.
Recent clinical trials have identified new and better ways to treat breast cancer. From exercise for anastrozole arthralgias to promising PARP inhibitors for triple-negative breast cancer, there are many advances.